Company: Dr. Reddy's Laboratories Ltd.


The company reported revenue growth of 13.4% yoy to Rs4,029.6cr, broadly in-line with consensus estimates.
May 20, 2019, 3:16 p.m.

The revenues from India during the Q4 was at ₹650 crore.For FY19, PAT stood at ₹1,880 crore while revenue was 15,385 crore
May 17, 2019, 7:40 p.m.
Publisher: livemint.com

Divestment of derma assets, lower operating costs helped firm post higher profit growth during the quarter
May 17, 2019, 7:26 p.m.

Dr Reddy’s Laboratories Ltd reported that its consolidated net profit increased by 44 per cent at Rs 434 crore in the fourth quarter ended March 31,
May 17, 2019, 4:15 p.m.


NULL
May 17, 2019, 3:50 p.m.
Publisher: moneycontrol.com

NULL
May 17, 2019, 3:50 p.m.
Publisher: moneycontrol.com

Revenue for the quarter under discussion was up by 14 per cent at Rs 4,016.60 crore against Rs 3,534.90 crore in the same quarter last fiscal
May 17, 2019, 3:42 p.m.

Revenue for the quarter under discussion was up by 14 per cent at Rs 4,016.60 crore against Rs 3,534.90 crore in the same quarter last fiscal
May 17, 2019, 3:42 p.m.

The Cubicin for Injection (daptomycin for injection) brand and generic had US sales of ~$640.8mn MAT for the most recent twelve months ending in March 2019, according to IQVIA Health.
May 15, 2019, 12:40 p.m.

Shares of the drugmaker have gained 38 percent in the past 12 months, beating peers.
May 10, 2019, 10:31 a.m.

-->